Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2018 Mar 8;8(8):2242-2244.
doi: 10.7150/thno.25181. eCollection 2018.

OVOL2 in metastasis prevention in NPC

Kyung-A Song  1 , Anthony C Faber  1
Affiliations
Editorial

OVOL2 in metastasis prevention in NPC

Kyung-A Song et al. Theranostics. .

Abstract

Metastasis remains a critical - and largely elusive - target in the race to prevent cancer-related deaths. Such is true in nasopharyngeal carcinoma (NPC), where the presentation or development of metastatic disease is usually fatal. In this edition of Theranostics, Qi et al. demonstrate a critical role of the zinc-finger transcription factor, OVOL2, in suppressing metastasis and maintaining an epithelial phenotype. These data add to the depth of understanding of the metastatic program in NPC, and may eventually lead to a druggable target in late-stage NPC.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Proposed model of the influence of OVOL2 on the EMT process in nasopharyngeal carcinoma (NPC). OVOL2 is a key transcription factor in epithelial-mesenchymal transition in NPC. Major EMT markers regulated by OVOL2 as demonstrated in epithelial (S26 and CNE2) and mesenchymal (OVOL2-knockout (KO) and S18) cells. OVOL2 negatively regulates stemness, and affects metastasis and drug resistance by inhibiting the EMT inducer, ZEB1.
See this image and copyright information in PMC

Comment on

References

    1. Huang J, Li Q, Zheng Y, Shen J, Li B, Zou R. et al. Partial hepatectomy for liver metastases from nasopharyngeal carcinoma: a comparative study and review of the literature. BMC cancer. 2014;14:818.. doi:10.1186/1471-2407-14-818. - PMC - PubMed
    1. Li JX, Lu TX, Huang Y, Han F, Chen CY, Xiao WW. [Clinical features of 337 patients with recurrent nasopharyngeal carcinoma] Chin J cancer. 2010;29:82–6. - PubMed
    1. Tan WL, Tan EH, Lim DW, Ng QS, Tan DS, Jain A. et al. Advances in systemic treatment for nasopharyngeal carcinoma. Chin Clin Oncol. 2016;5:21.. doi:10.21037/cco.2016.03.03. - PubMed
    1. Zhang W, Zeng Z, Zhou Y, Xiong W, Fan S, Xiao L. et al. Identification of aberrant cell cycle regulation in Epstein-Barr virus-associated nasopharyngeal carcinoma by cDNA microarray and gene set enrichment analysis. Acta Biochim Biophys Sin (Shanghai) 2009;41:414–28. - PubMed
    1. Zeisberg M, Neilson EG. Biomarkers for epithelial-mesenchymal transitions. J Clin Invest. 2009;119:1429–37. doi:10.1172/jci36183. - PMC - PubMed

LinkOut - more resources